

**Luxembourg - More stringent blood donor testing requirements
2015 Mapping exercise**

Colour key	
	Minimum requirements as set out in the 2004/33/EC Directive
	More stringent testing - legally binding on national level
	More stringent testing - recommended on national level
	Not legally binding and not recommended on national level

Test	Test/ technique	Legally binding	Recommendation on national level	Recommending authority/ service/ association	Type of blood donation (blood for transfusion or plasma for fractionation)	Circumstances for application/ donor profile	Regional differences	Further comments
Basic testing								
Blood group testing	ABO typing	YES	YES	National competent authority	both	all donations	NO	Control of bags for ABO after production is added.
	RhD typing	YES	YES	National competent authority	both	all donations	NO	Control of bags for D- after production is added.
	Irregular antibodies	YES	YES	National competent authority	both	all donations	NO	From 2016, detection will be done once a year.
	Other, please specify (Kell etc.)							Many regular donors have a phenotype Kidd, Duffy, MNS, ... for recipients with allo-Ab or for designated or directed donations.
HLA testing								
Disease testing								
VIRAL								
HIV 1 and HIV 2	Anti-HIV 1	YES	YES	http://www.legilux.public.lu/leg/a/archive	both	all donations	NO	A combined test for the detection of the Ab and Ag P24 is used.
	Anti-HIV 2	YES	YES	http://www.legilux.public.lu/leg/a/archive	both	all donations		
	HIV 1p24							
	HIV NAT pool or ID	NO	YES	CD-P-TS Guide to the preparation, use and quality assurance of blood components	both	all donations		
	HIV NAT ID Other technique							
Hepatitis B	HBs Ag	YES	YES	http://www.legilux.public.lu/leg/a/archive	both	all donations	NO	
	Anti-HBc	NO	YES	CD-P-TS Guide to the preparation, use and quality assurance of blood components	whole blood/ blood components for transfusion	New donors		
	Anti - HBs							
	HBV NAT pool or ID HBV NAT ID Other technique	NO	YES	CD-P-TS Guide to the preparation, use and quality assurance of blood components	both	all donations		
Hepatitis C	Anti-HCV	YES	YES	http://www.legilux.public.lu/leg/a/archive	both	all donations	NO	
	HCV NAT pool or ID	NO	YES	CD-P-TS Guide to the preparation, use and quality assurance of blood components	both	all donations		
	HCV NAT ID							
	Other technique							
Hepatitis E	HEV/ technique not specified						NO	A toll manufacturing agreement with Octapharma exists for FFPsd (group A and O) and apheresis plasma B and AB is sold to Octapharma for FFPsd B and AB.
	Anti-HEV							
	HEV NAT pool or ID	NO	YES	Requirement for FFPsd regarding certification OMCL (quality assurance agreement with Octapharma)	plasma for fractionation	only for all donations of plasma apheresis		
	HEV NAT ID Other technique							
Hepatitis A	HVA NAT pool or ID	NO	YES	Requirement for plasma fractionation with Octapharma (quality assurance agreement)	both	all donations	NO	Plasma of WB donations and plasmapheresis is sold to Octapharma for fractionation.
HTLV-1	HTLV-1/ technique not specified						NO	Western blot is used for a positive result (algorithm).
	Anti-HTLV-1	NO	YES	CD-P-TS Guide to the preparation, use and quality assurance of blood components	whole blood/ blood components for transfusion	New donors		
	HTLV-1 NAT pool or ID HTLV-1 NAT ID Other technique							
	Other technique							
HTLV-2	HTLV-2/ technique not specified						NO	Western blot is used for a positive result (algorithm).
	Anti-HTLV-2	NO	YES	CD-P-TS Guide to the preparation, use and quality assurance of blood components	whole blood/ blood components for transfusion	New donors		
	HTLV-2 NAT pool or ID HTLV-2 NAT ID Other technique							
	Other technique							
Ebola Virus								Deferral during 6 months after a stay in tropical area.
Chikungunya virus								Deferral during 6 months after a stay in tropical area.
Cytomegalovirus	CMV/ technique not specified						NO	Platelets are treated with mirasol (PI) and a serology (IgG) for red cells is done.
	Anti-CMV	NO	YES	CD-P-TS Guide to the preparation, use and quality assurance of blood components	whole blood/ blood components for transfusion	immunodeficient recipient		
	CMV NAT pool or ID CMV NAT ID Other technique							
	Other technique							
West Nile Virus	WNV/ technique not specified						NO	

**Luxembourg - More stringent blood donor testing requirements
2015 Mapping exercise**

Test	Test/ technique	Legally binding	Recommendation on national level	Recommending authority/ service/ association	Type of blood donation (blood for transfusion or plasma for fractionation)	Circumstances for application/ donor profile	Regional differences	Further comments
	WNV NAT pool or ID	NO	YES	Final working group document 2012 V.2.1. WNV and blood safety introduction to a preparedness plan in Europe	both	For donations during 28 days after return from endemic areas		
	WNV NAT ID*							
	Other technique							
Dengue Virus								Deferral during 6 months after a stay in tropical area.
Epstein-Barr virus								For donors with adenopathies or mononucleosis syndrome.
Human Parvovirus B19	HPVB19/ technique not specified			Requirement regarding the quality assurance agreement with Octapharma for the sale of plasma	both	all donations	NO	The law indicates that the test should be done for different diseases and that more tests can be required.
	HPVB19 NAT pool or ID	NO	YES					
	HPVB19 NAT ID Other technique							
Herpes simplex virus								
Nonspecific viral infection								
Other pathogen,								
Malaria	Technique not specified			http://www.legilux.public.lu/leg/a/archives/2006/0043/a043.pdf#page=2	whole blood/ blood components for transfusion	Donor history of disease and permanence in endemic regions	NO	
	Microscopy	YES	YES					
	<i>Plasmodium sp.</i> Ab							
	<i>Plasmodium sp.</i> Ag <i>Plasmodium sp.</i> Ag - rapid test							
	<i>Plasmodium sp.</i> NAT pool or ID <i>Plasmodium sp.</i> NAT ID Other technique							
Trypanosomiasis	Technique not specified			CD-P-TS Guide to the preparation, use and quality assurance of blood components	whole blood/ blood components for transfusion	New donors from endemic areas	NO	
	Microscopy	NO	YES					
	Anti-Trypanosoma cruzi							
	<i>T. cruzi</i> NAT pool or ID <i>T. cruzi</i> NAT ID Other technique							
Babesiosis								Permanent deferral.
Leishmaniasis								Permanent deferral.
Toxoplasmosis								For donors with adenopathies or mononucleosis syndrome.
Other pathogen,								
BACTERIAL								
Treponema pallidum (Syphilis)	Technique not specified			http://www.legilux.public.lu/leg/a/archiv	both	all donations	NO	
	Microscopy	YES	YES					
	Anti-T. pallidum							
	<i>T. pallidum</i> NAT pool <i>T. pallidum</i> NAT ID Culture							
Neisseria gonorrhoeae								
Brucellosis								
Tuberculosis								
Q-fever								deferral: 2 years.
Other pathogen,								
FUNGI								
specify pathogen								

* For West Nile Virus NAT ID, see 2004/33/EC as amended by 2014/110/EU with a deadline for transposition into national law of December 31, 2015